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Abstract
Background: Dietary intervention is the cornerstone of non-alcoholic steatohepatitis (NASH) treatment. However,
histological evidence of its efficacy is limited and its impact on hepatic pathways involved in NASH is
underreported. The efficacy of the angiotensin receptor type 1 blocker losartan is controversial because of varying
results in a few animal and human studies. We evaluated the effect of dietary intervention versus losartan on NASH
and associated systemic metabolic features in a representative mouse model.
Methods: Male C57BL/6 J mice with high fat-high sucrose diet (HF-HSD) induced NASH, obesity, insulin resistance
and hypercholesterolemia were subjected to dietary intervention (switch from HF-HSD to normal chow diet (NCD))
(n = 9), continuation HF-HSD together with losartan (30 mg/kg/day) (n = 9) or continuation HF-HSD only (n = 9) for
8 weeks. 9 mice received NCD during the entire experiment (20 weeks). We assessed the systemic metabolic effects
and performed a detailed hepatic histological and molecular profiling. A P-value of < 0.05, using the group with
continuation of HF-HSD only as control, was considered as statistically significant.
Results: Dietary intervention normalized obesity, insulin resistance, and hypercholesterolemia (for all P < 0.001), and
remarkably, completely reversed all histological features of pre-existent NASH (for all P < 0.001), including fibrosis
measured by quantification of collagen proportional area (P < 0.01). At the hepatic molecular level, dietary intervention
targeted fibrogenesis with a normalization of collagen type I alpha 1, transforming growth factor β1, tissue inhibitor of
metalloproteinase 1 mRNA levels (for all P < 0.01), lipid metabolism with a normalization of fatty acid translocase/CD36,
fatty acid transport protein 5, fatty acid synthase mRNA levels (P < 0.05) and markers related to mitochondrial function
with a normalization of hepatic ATP content (P < 0.05) together with sirtuin1 and uncoupling protein 2 mRNA levels (for
both P < 0.001). Dietary intervention abolished p62 accumulation (P < 0.01), suggesting a restoration of autophagic flux.
Losartan did not significantly affect obesity, insulin resistance, hypercholesterolemia or any histological NASH feature.
Conclusions: Dietary intervention, and not losartan, completely restores the metabolic phenotype in a representative
mouse model with pre-existent NASH, obesity, insulin resistance and hypercholesterolemia.
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Background
Non-alcoholic fatty liver disease (NAFLD) is the most
prevalent liver disease in the Western world, affecting
20–30% of the adult population [1]. Due to its strong
pathophysiological and epidemiological association with
obesity, insulin resistance, dyslipidemia and hyperten-
sion, NAFLD is considered as the hepatic manifestation
of the metabolic syndrome [2]. NAFLD is the collective
noun for a spectrum of histological abnormalities ran-
ging from isolated steatosis to nonalcoholic steatohepati-
tis (NASH). The latter is characterized by steatosis,
hepatocyte ballooning and inflammation with or without
fibrosis [3]. NASH can progress to cirrhosis and related
complications, including hepatocellular carcinoma [4].
As a consequence, NASH is the most rapidly rising indi-
cation for liver transplantation [5, 6].
This societal and medical relevance of NASH has in-
spired numerous animal studies and human trials in
order to find an effective treatment. Dietary modification
and physical exercise remain the cornerstones of treat-
ment, although available evidence that these measures
can reverse NASH is rather limited [7–11]. When ap-
plied together, they may dose-dependently improve the
histological features of NASH in a subset of patients, as
shown in two clinical trials [8, 11]. Data on the histo-
logical effects of diet only interventions on established
NASH are even more scarce [10]. However, knowledge
of the therapeutic potential of dietary intervention is im-
portant, not in the least for patients who cannot increase
their level of physical exercise due to physical limitations
or lack of time. Furthermore, the mechanisms behind
the possible beneficial effects of dietary intervention re-
main largely underexplored [12].
In addition, not a single pharmacological agent has been
approved for the treatment of NASH so far [7, 9, 13]. Re-
search efforts rather improved the insight in NASH patho-
physiology, including the role of the renin-angiotensin
system (RAS). In the liver, angiotensin II, the main effector
of the RAS, is thought to play a role in the development
and progression of NASH, possibly by the generation of
oxidative stress and inflammatory cytokines leading to
steatosis, inflammation and fibrosis [14]. Therefore, at-
tenuating the effects of angiotensin II by administering
losartan, an angiotensin II type 1 receptor blocker, could
be beneficial for NASH and other components of the
metabolic syndrome [14]. However, in vivo evidence re-
garding the efficacy of losartan is only based on a few
studies in non-physiological animal models and two hu-
man pilot trials with each a limited number of patients
[14–17]. The lack of efficacy of losartan in other studies,
further fueled the controversy [18, 19].
Previously, we developed a NASH mouse model in-
duced by the administration of a ‘Western’ high fat-high
sucrose diet (HF-HSD), with close resemblance to the
hepatic and systemic metabolic profile of typical NASH
patients [20]. In the current study, we assessed the
therapeutic efficacy of dietary intervention (based on a
switch from HF-HSD to normal chow diet) and losartan
in this mouse model with pre-existent NASH, insulin re-
sistance, obesity and hypercholesterolemia.
Methods
Animals, diet and experimental set-up
Male C57BL/6 J mice (The Jackson Laboratory, Bar
Harbor, Maine, USA) were housed under a 14 h light-
10 h dark cycle at 21–23 °C and had ad libitum access to
water during the entire experiment. Mice were fed a
‘Western’ high fat-high sucrose diet (HF-HSD) with 44.6%
of kcal derived from fat (of which 61% saturated fatty
acids) and 40.6% of kcal derived from carbohydrates (pri-
marily sucrose 340 g/kg diet) (TD.08811, 45%kcal Fat
Diet, Harlan Laboratories Inc., Madison, WI, USA) or a
normal chow diet (NCD) (V1534-000 ssniff R/M-H, ssniff
Spezialdiäten GmbH, Soest, Germany). Losartan (30 mg/
kg bodyweight/day) (Cayman Chemical Company, Ann
Arbor, MI, USA) was administered via drinking water.
Food intake per cage (n = 3–4 mice per cage) was mea-
sured when renewing the pellets weekly. The drinking
water with losartan was renewed daily.
We applied a curative set-up, wherein 27 mice were
fed a HF-HSD for 12 weeks (started at age of 6 weeks)
to induce the phenotype with NASH, obesity, insulin
resistance and hypercholesterolemia, as we published
previously [20, 21]. Subsequently, the mice were ran-
domized to the different intervention groups (Fig. 1):
1) HF-HSD group: continuation HF-HSD for the
remaining 8 weeks (n = 9); 2) HF-HSD-LOS group:
continuation HF-HSD together with losartan for the
remaining 8 weeks (n = 9) and 3) Return to NCD
group: switch from HF-HSD to NCD (ad libitum) for
the remaining 8 weeks of the experiment (n = 9). 9
mice received NCD during the entire experiment
(20 weeks) (NCD group). Mean food intake during
these last 8 weeks of the experiment was 3.40 g/
mouse/day (≈10.37 kcal/mouse/day) for the NCD
group, 2.85 g/mouse/day (≈ 13.39 kcal/mouse/day) for
the HF-HSD group, 2.74 g/mouse/day (≈ 12.87 kcal/
mouse/day) for the HF-HSD-LOS group and 2.88 g/
mouse/day (≈ 8.78 kcal/mouse/day) for the Return to
NCD group. All procedures were approved by the ani-
mal welfare committee of the University of Leuven
(protocol number: P088/2011).
In vivo phenotyping
Body weight was monitored weekly on the same day.
Two weeks before sacrifice, intra-peritoneal glucose tol-
erance test (IPGTT) was performed in 6 h fasted mice.
Tail vein glucose levels were measured with a Bayer
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Contour® glucometer immediately before (time point
0 min) and 15, 30, 60, 90 and 150 min after glucose ad-
ministration (1 g glucose/kg bodyweight). Insulin resist-
ance was estimated using the Homeostasis Model of
Insulin Resistance (HOMA-IR) index: (fasting insulin
(ng/ml) X fasting glucose (mg/dl))/405 [22].
Sacrifice
Sacrifice was performed as described previously [20]. After
a 6 h fasting period, mice were anesthetized with sodium
pentobarbital (i.p. injection, 50 mg/kg body weight) and
killed by blood sampling via cardiac puncture. Plasma was
obtained by centrifugation of blood (6000 rpm for 5 min at
4 °C) that was collected in heparinized syringes. Tissues
were either snap frozen in liquid nitrogen and together with
the plasma stored at -80 °C till further biochemical and mo-
lecular analyses or preserved for histological analysis.
Biochemical analyses
Alanine aminotransferase (ALT) and total cholesterol were
measured on 200 μl plasma, obtained through cardiac
puncture at sacrifice, via automated procedures. Plasma in-
sulin was measured with a mouse Insulin Elisa Kit (Crystal
Chem Inc., Downers Grove, IL, USA). ATP content was
measured in liver tissue after homogenization in RIPA lysis
buffer (1× PBS, 1% Nonidet P-40, 0.5% sodium deoxycho-
late, 0.1% SDS, 1 mM sodium orthovanadate (Na3VO4),
200 mM phenylmethanesulfonylfluoride (PMSF) in isopro-
panol, protease inhibitor cocktail), using the CellTiter-Glo
Luminescent Cell Viability Assay (Promega Corp., Madison,
WI, USA) according to the manufacturer’s instructions. 4-
Hydroxynonenal (HNE), a byproduct of lipid peroxidation
and thus a marker of oxidative stress, was measured follow-
ing the manufacturer’s protocol (OxiSelect HNE-His
Adduct ELISA Kit, Cell Biolabs Inc., San Diego, CA, USA).
RNA isolation and quantitative RT-PCR
At sacrifice, tissue samples were collected for RNA
isolation and stored at -80 °C until analysis. RNA was
obtained by a two-step procedure. First, the RNA was
isolated using the Trizol method according to the
manufacturer’s instructions (Invitrogen Life Technolo-
gies, Ghent, Belgium) and was further purified with
the RNeasy Kit (Qiagen, Chatsworth, CA, USA). One
microgram of cellular RNA was reverse transcribed
into cDNA using SuperScript II reverse transcriptase
and random hexamer primers (Invitrogen Life Technolo-
gies, Ghent, Belgium). The PCR reaction was carried out
in a mixture that contained appropriate sense- and anti-
sense primers and a TaqMan MGB probe in TaqMan
Universal PCR Master Mixture (Applied Biosystems,
Foster City, CA, USA) (Col1a1: Mm00801666_g1, TGF-
β1: Mm01178820_m1, Timp1: Mm00441818_m1, FAT/
CD36: Mm01135198_m1, FATP5: Mm00447768_m1,
SREBP-1c: Mm00550338_m1, FAS: Mm00662319_m1,
ACC1: Mm01304257_m1, PPAR-α: Mm00440939_m1,
CPT1A: Mm01231183_m1, MCAD: Mm01323360_g1,
PGC1-α: Mm01208835_m1, SIRT1: Mm00490758_m1,
UCP2: Mm00627599_m1, TNF-α: Mm00443260_g1, p62:
Mm00448091_m1 and Atg3: Mm00471287_m1. Beta-2-
microglobulin was used as housekeeping gene (B2M:
Mm00437762_m1). Real-time PCR amplification and data
analysis were performed using the A7500 Fast Real-Time
PCR System (Applied Biosystems, Foster City, CA, USA).
Each sample was assayed in duplicate in a MicroAmp op-
tical 96-well plate. The ΔΔCt-method was used to deter-
mine relative gene expression levels.
Western blot
Liver samples were homogenized with the Precellys
24 tissue homogenizer (Bertin Technologies, distrib-
uted by VWR, Leuven, Belgium) in a buffer contain-
ing 20 mM Tris-HCl pH 7.6, 10% glycerol, 1%
Nonidet P-40, 2 μg/ml aprotinin, 5 μg/ml leupeptin,
0.5 μg/ml pepstatin, 10 mM sodium orthovanadate,
34 μg/ml phenylmethylsulfonyl fluoride, 10 mM so-
dium pyruvate, 100 mM sodium fluoride and 10 mM
EDTA. Coomassie Protein Assay Reagent (Pierce
Fig. 1 Experimental design. Losartan was given in a dose of 30 mg/kg/day via drinking water
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Biotechnology Inc., Rockford, IL, USA) in combin-
ation with a standard curve of bovine serum albumin
was used to determine the corresponding protein
content of the homogenates.
Western blots for autophagic markers were performed
as described previously [23]. Primary antibodies were pur-
chased from Abcam, Cambridge, UK (microtubule-associ-
ated protein-1 light chain 3 (LC3) and actin) or Novus
Biologicals, Littleton, CO, USA (p62). Secondary anti-
bodies were obtained from DakoCytomation, Glostrup,
Denmark (horseradish peroxidase-conjugated goat-anti-
rabbit or goat-anti-mouse antibodies). Actin expression
was used to control for equal loading. Relative protein
levels were normalized to the mean of the ratio in the
NCD mice.
Histological analyses
Histological analyses were performed as described previ-
ously [20]. Liver samples were routinely fixed in buffered
formalin (4%) and embedded in paraffin. Serial 4 μm
thick sections were stained with hematoxylin and eosin
(H&E) and picrosirius red to assess fibrosis. All liver bi-
opsies were analysed by an expert liver pathologist,
blinded to the dietary condition or pharmacological
intervention. Steatosis, activity and fibrosis were semi-
quantitatively scored according to the NASH-Clinical
Research Network criteria [24]. The amount of steatosis
(percentage of hepatocytes containing fat droplets) was
scored as: 0 (<5%), 1 (5–33%), 2 (>33–66%) and 3
(>66%). Hepatocyte ballooning was classified as: 0
(none), 1 (few) or 2 (many cells/prominent ballooning).
Foci of lobular inflammation were scored as 0 (no foci),
1 (<2 foci per 200× field), 2 (2–4 foci per 200× field) and
3 (>4 foci per 200× field). Fibrosis was scored as stage
F0 (no fibrosis), stage F1a (mild, zone 3, perisinusoidal
fibrosis), stage F1b (moderate, zone 3, perisinusoidal fi-
brosis), stage F1c (portal/periportal fibrosis), stage F2
(perisinusoidal and portal/periportal fibrosis), stage F3
(bridging fibrosis) and stage F4 (cirrhosis). Diagnosis of
NASH was based on accepted histological criteria [25,
26]. Severity of the disease was assessed using the NAS
(nonalcoholic fatty liver disease activity score) as the un-
weighted sum of scores of steatosis, hepatocyte balloon-
ing and lobular inflammation [24]. Percentage of fibrosis
was quantitated by morphometry from digitalized sirius
red stained sections using the Aperio system after tuning
the threshold of fibrosis detection under visual control.
Result is expressed as collagen proportional area [27].
Statistical analyses
Statistical analyses were performed with GraphPad
Prism version 6 (GraphPad Software, La Jolla, CA, USA)
and JMP10.0.0 (SAS Institute Inc, Cary, NC, USA). Sig-
nificant differences were estimated by one-way ANOVA
and Tukey post-hoc analysis (parametric samples) or
Kruskal-Wallis and Dunn’s multiple comparisons test
(nonparametric samples). A P-value of < 0.05 was con-
sidered as statistically significant. Significance is repre-
sented by: *: P < 0.05, **: P < 0.01 and ***: P < 0.001. Error
bars are standard error of mean (SEM).
Results
Dietary intervention normalizes obesity, insulin resistance
and hypercholesterolemia
Mice in which the HF-HSD was switched to NCD (Re-
turn to NCD), displayed a normalization of body weight
(Fig. 2a) and epididymal fat pad weight (Fig. 2b). In
addition, dietary intervention normalized glucose levels
during IPGTT (Fig. 2c), HOMA-IR (Fig. 2d) and plasma
total cholesterol levels (Fig. 2e).
On the contrary, losartan did not have an effect on
established obesity. Body weight (Fig. 2a) and epididymal
fat pad weight (Fig. 2b) were not different between the
HF-HSD and HF-HSD-LOS group. Losartan did not
affect glucose homeostasis. We observed no significant
differences in glucose levels during IPGTT (Fig. 2c) or
HOMA-IR (Fig. 2d) between HF-HSD and HF-HSD-
LOS mice. Plasma total cholesterol levels were not influ-
enced by losartan (Fig. 2e).
Dietary intervention, in contrast with losartan, completely
reverses pre-existent NASH and fibrosis
Remarkably, switch from HF-HSD to NCD in mice with
NASH, completely reversed steatosis, hepatocyte bal-
looning, inflammation and fibrosis (Fig. 3a). Histological
scores of Return to NCD mice were identical to that of
mice that were fed a NCD during the entire experiment
(Fig. 3b and c). In correspondence, morphometric as-
sessment showed a significant decrease of collagen pro-
portional area in Return to NCD mice (Fig. 3d). In
addition, liver weight and plasma alanine transaminase
(ALT) levels (as a marker of liver damage) were normal-
ized by the dietary intervention (Fig. 3e and f).
Losartan did not improve nor halt the progression
of pre-existent NASH (Fig. 3a). Steatosis, hepatocyte
ballooning, inflammation and fibrosis scores did not
differ between HFD-HSD and HF-HSD-LOS mice
(Fig. 3b and c). Collagen proportional area, liver
weight and plasma ALT levels were not significantly
affected by losartan (Fig. 3d-f ).
Dietary intervention targets several pathways involved in
NASH
In agreement with the histological findings, dietary
intervention (Return to NCD) normalized hepatic
mRNA levels of genes involved in fibrogenesis (Col1a1,
TGF-β1, Timp1) (Fig. 4a). Furthermore, dietary inter-
vention targets lipid metabolism. mRNA levels of genes
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involved in fatty acid uptake/transport (FAT/CD36 and
FATP5) (Fig. 4b) and lipogenesis (FAS) (Fig. 4c) were
normalized in Return to NCD mice.
At least on mRNA level, we observed no significant
differences in fatty acid β-oxidation between the diet-
ary groups at the moment of sacrifice (Fig. 5a). This
probably can be explained by the decline of an initial
increase of fatty acid β-oxidation in NASH, as we
demonstrated previously, which also might be the
case after dietary intervention [20]. Dietary interven-
tion affects other parameters involved in mitochon-
drial function. mRNA levels of SIRT1 (key regulator
of mitochondrial function), TNF-α (inducer of mito-
chondrial dysfunction) and UCP2 (uncouples oxida-
tion from ATP synthesis) were normalized in Return
to NCD mice (Fig. 5b). In addition, hepatic ATP
levels were restored after dietary intervention (Fig. 5c).
Hepatic HNE content (marker of oxidative stress) was
not significantly decreased in Return to NCD mice
(Fig. 5d). This indicates that oxidative damage by it-
self is not sufficient to sustain the NASH phenotype
in our set-up.
Hepatic protein levels of p62 (a protein directing
ubiquitinated proteins to the autophagic machinery
that is known to accumulate when autophagy is im-
paired or insufficient) were increased in HF-HSD
mice (Fig. 6a). In the absence of an increase in p62
mRNA levels (Fig. 6b), the p62 protein accumulation
thus suggests an impaired autophagic flux [23, 28].
Disturbed autophagy in HF-HSD mice is further sup-
ported by reduced mRNA levels of Atg3 (Fig. 6c).
Dietary intervention abolished the p62 protein accu-
mulation and returned Atg3 mRNA to normal levels,
suggesting restoration of the autophagic flux (Fig. 6a-
c). The LC3-II/LC3-I ratio, which is used as a marker
of mature autophagosome formation, was not affected
by HF-HSD or the dietary intervention (data not
shown).
Fig. 2 Systemic metabolic effects of dietary intervention (Return to NCD) and losartan (HF-HSD-LOS). a Progression of body weight (n = 9 per
group). b Epididymal fat pad weight (n = 9 per group). c Intra-peritoneal glucose tolerance test (6 h fasting, 1 g/kg glucose) with associated area
under the curve values, determined 2 weeks before sacrifice (n = 9 for HF-HSD and HF-HSD-LOS mice and n = 6 for NCD and Return to NCD
mice). d HOMA-IR (fasting glucose (mg/dl) X fasting insulin (ng/ml)/405) at sacrifice (n = 8 per group). e Fasting plasma total cholesterol (n = 9 per
group). Asterisks indicate significant difference versus HF-HSD mice. Data are presented as mean. Error bars are SEM
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Finally, losartan significantly decreased mRNA levels of
FAT/CD36, FAS and UCP2, but did not affect any other
of the aforementioned parameters (Figs. 4, 5 and 6).
Discussion
In this study, dietary intervention completely reversed
all features of pre-existent NASH, together with obesity,
insulin resistance and hypercholesterolemia in a repre-
sentative mouse model. Losartan had no effect on these
established metabolic changes.
The beneficial effect of life style intervention on
NASH, focused on both dietary and exercise habits,
has been demonstrated in only a few randomized con-
trolled trials with histological endpoints [8, 10, 11]. In
addition, human studies are limited in time and do
not allow clear differentiation of the dietary effects
relative to physical activity [7, 10]. Moreover, only 30
to 40% of patients achieve target weight loss even in
trials implementing an intensive life style program in-
cluding behavorial strategies, which reflects the vari-
able patient adherence [8, 10, 11, 29]. Therefore, we
opted to use a relevant NASH mouse model to explore
the full therapeutic potential of dietary intervention,
which additionally allowed us to study the hepatic
mechanisms behind it. To our knowledge, our dietary
intervention represents the most effective therapy for
NASH (i.e., complete resolution) demonstrated in ro-
dents. Dietary intervention also resolved fibrosis in
our model. This is an important finding since fibrosis
is the major determinant for progression to end-stage
Fig. 3 Effects on liver histology of dietary intervention (Return to NCD) and losartan (HF-HSD-LOS). a Representative hematoxylin and eosin (H&E)
and picrosirius red stained liver histology images per dietary group. b Steatosis, hepatocyte ballooning, inflammation scores and NAFLD activity
score (NAS). c Fibrosis score. d Morphometric analysis of collagen proportional area. e Liver weight. f Plasma ALT. Asterisks indicate significant
difference versus HF-HSD mice. N = 9 per group for all assays. Data are presented as mean. Error bars are SEM
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liver disease and thus represents a main target to com-
bat in NASH [20, 30, 31]. In 3 recent studies, a com-
parable dietary intervention (switch from a high fat
diet to a NCD) was applied in obese mice with NASH
[12, 32, 33]. However, the beneficial effects on liver
histology were less pronounced, likely due to the
shorter length of the dietary intervention (3 weeks) in
one study and the use of genetically modified mice
(hyperphagic foz/foz (Alms1 mutant) and low-density
lipoprotein receptor knock out mouse model) in the
two other studies [12, 32, 33].
The fact that dietary intervention affects the precipi-
tating insult and in addition has the ability to normalize
several molecular pathways involved in NASH, probably
explains its superior efficacy compared with pharmaco-
logical agents that mostly only target a single or limited
number of relevant pathways. We showed that dietary
intervention targets pathways involved in fibrogenesis,
lipid metabolism, mitochondrial function and autophagy,
together contributing to the beneficial effect on histo-
logical level. The time point of sacrifice was 8 weeks
after return to NCD. The study of earlier time points
may clarify the possibility that a burst of clean-up of ac-
cumulating lipids by fatty acid oxidation and possibly
autophagy took place in earlier stages after the dietary
switch.
In contrast with our animal study, life style interven-
tions (including dietary counselling) yield rather disap-
pointing results in daily patient care. The lack of a well-
organized multidisciplinary therapeutic approach from
physician’s side probably reinforces this phenomenon
[34, 35]. Therefore, in order to exploit the maximal
therapeutic potential of dietary intervention, improving
patient adherence, possibly by cognitive behaviour ther-
apy embedded in structured programs, should be a main
goal in the care of NASH patients in the coming years
[35]. The lack of effective pharmacological alternatives
and the additional beneficial effect of life style measures
on other components of the metabolic syndrome further
support this strategy.
However, more insight is needed in the role of specific
dietary components in NASH treatment strategies. The evi-
dence for the harmful effects of saturated fatty acid and su-
crose intake is solid, whereas the preventive or even
therapeutic capacity of specific dietary components (i.e.,
nutraceutical products) is less clear in the context of NASH
[36, 37]. Animal studies using ingredient matched control
diets or well-designed human interventional studies could
provide further insight. This might potentiate the use of
these molecules as therapeutics and explain the possible
beneficial effects of the Mediterranean diet in NAFLD/
NASH [36, 37]. Another issue that remains to be addressed
is the influence of genetic variation in humans (in contrast
with the inbred C57BL/6 J mouse strain we used for our
experiments) on treatment outcome. Very little is known
about the effect of genetics on the response to dietary or
pharmacological treatment of NASH [38]. It was recently
shown that genetic variation in PNPLA3 (adiponutrin) in-
deed confers sensitivity to weight loss-induced decrease of
liver fat in humans [39]. Therefore, identifying (genetic)
predictors for response to treatment could potentiate an in-
dividualized approach, stimulate patients to persevere the
necessary dietary changes and increase their physical activ-
ity, and may thus further improve clinical outcome [38].
Fig. 4 Effect of dietary intervention (Return to NCD) and losartan (HF-HSD-LOS) on fibrogenesis and hepatic lipid metabolism. a mRNA levels of
genes involved in fibrogenesis (Collagen type I alpha 1 (Col1a1), transforming growth factor β1 (TGF-β1) and tissue inhibitor of metalloproteinase
1 (Timp1)). b mRNA levels of genes involved in fatty acid transport (Fatty acid translocase/cluster of differentiation 36 (FAT/CD36), fatty acid
transporter member 5 (FATP5)). c mRNA levels of genes involved in lipogenesis (Sterol regulatory element binding transcription factor 1 (SREBP1c),
fatty acid synthase (FAS), acetyl-CoA carboxylase 1 (ACC1)). Asterisks indicate significant difference versus HF-HSD mice. N = 9 per group for all assays.
Data are presented as mean. Error bars are SEM
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In parallel, we explored the therapeutic potential of
losartan. Losartan seems an attractive candidate for
the treatment of NASH, because it is a safe drug
widely used for the treatment of hypertension (which
is a part of the metabolic syndrome) and it targets
angiotensin II that is thought to play an important
role in NASH [14, 40]. However, the few available
preliminary human and animal studies yielded equivo-
cal results [14–19]. In addition, losartan has only
been tested in normal or hyperphagic Otsuka Long-
Evans Tokushima fatty (OLETF) rats, which were fed
a non-physiological choline-deficient L-amino acid-
defined diet [16, 18]. In our representative HF-HSD
model, losartan did not have a beneficial effect on
established NASH, obesity and insulin resistance. At
the molecular level, losartan only significantly de-
creased FAT/CD36 and FAS mRNA together with
UCP2 mRNA, but these effects appear insufficient to
impact hepatic steatosis or ATP content respectively.
We used a losartan dose comparable to the dose used
in previous rodent studies on the metabolic and car-
diovascular effects of losartan [41]. It may be that the
duration of losartan administration in our experimen-
tal set-up was not long enough, although the same
intervention period was largely sufficient to resolve
NASH and associated systemic metabolic features by
dietary intervention. However, in contrast with the
dietary switch group, losartan had to counteract the
effects of the continued HF-HSD, mimicking the hu-
man obesiogenic environment. It might be interesting
to explore whether higher losartan doses, a longer ad-
ministration time or losartan in combination with
dietary intervention or another drug would be effect-
ive in NASH resolution. Possibly, a better effect could
be achieved by using telmisartan, because of its com-
bination of peroxisome proliferator-activated receptor
(PPAR)-γ and angiotensin receptor blocking activity
[42, 43]. Taken together, our pre-clinical data do not
support the use of losartan to treat NASH.
Fig. 5 Effect of dietary intervention (Return to NCD) and losartan
(HF-HSD-LOS) on mitochondrial parameters. a mRNA levels of genes
involved in fatty acid β-oxidation: Peroxisome proliferator activated
receptor α (PPAR-α), carnitine palmitoyltransferase 1A (CPT1A) and
medium chain acyl-Coenzyme A dehydrogenase (MCAD). b mRNA
levels of genes involved in regulation of mitochondrial function
(Peroxisome proliferator-activated receptor gamma coactivator 1-α
(PGC1-α), Sirtuin1 (SIRT1), uncoupling protein 2 (UCP2) and tumor
necrosis factor-α (TNF-α)). c ATP content. d HNE concentration as
marker of oxidative stress. Asterisks indicate significant difference
versus HF-HSD mice. N = 9 per group for all assays. Data are presented
as mean. Error bars are SEM
Fig. 6 Effect of dietary intervention (Return to NCD) and losartan (HF-HSD-LOS) on hepatic autophagic parameters. a Protein levels of p62. b
mRNA levels of p62. c mRNA levels of autophagocytosis associated protein 3 (Atg3). Asterisks indicate significant difference versus HF-HSD mice.
N = 9 per group for all assays. Data are presented as mean. Error bars are SEM
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Conclusions
In contrast with losartan, dietary intervention completely
restores the metabolic phenotype, on both hepatic and sys-
temic level, in mice with pre-existent NASH, obesity, insu-
lin resistance and hypercholesterolemia. Our mouse model
and set-up represent a useful tool to further study the ef-
fects of dietary and pharmacological interventions in NASH
and the metabolic syndrome. In addition, our results
emphasize the need to identify the pathophysiological and
therapeutic barriers that preclude similar results in the
current treatment of human NASH. This would facilitate
the development of effective strategies to help patients to
implement and maintain a healthy diet style in order to
treat NASH and other components of the metabolic
syndrome.
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